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Summary
A higher rate of clinical events in poor clopidogrel and/or aspirin
responders was documented by using different methods to
measure platelet function, but no conclusive data about the ap-
propriate methodology to explore platelet reactivity are avail-
able.A total of 746 patients included in the cohort of the RE-
CLOSE trial who had successful drug-eluting stent implantation
were assessed for post-treatment residual platelet reactivity
(RPR) in platelet-rich plasma by 10 µM adenosine 5'-diphos-
phate (ADP), 1 mM arachidonic acid (AA) and 2 µg/ml collagen-
induced platelet aggregation and in whole blood by the PFA-100
system.At six-month follow-up, RPR by two stimuli (ADP and
AA orADP and collagen) and by three stimuli (ADP,AA and col-
lagen) is significantly associated with higher percentage of pri-
mary (definite or probable stent thrombosis) and secondary
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(cardiac mortality and stent thrombosis) end-points than RPR
by ADP,AA, collagen and PFA-100 system.According to the pri-
mary and secondary end points, the specificity values for RPR
identified by two (ADP andAA:94%;ADP and collagen:97%) and
three stimuli were higher with respect to RPR byADP (88%),or
RPR by AA (83%) or RPR by collagen (90%).The positive likeli-
hood ratio values of RPR by three stimuli (9.55) or of RPR by
ADP and collagen (8.08) were higher than those of RPR byADP
(2.59),byAA (2.05),by collagen (4.73),or by PFA-100 (2.63).This
prospective study documents that the evaluation of platelet
reactivity addressed to identify patients at risk of thrombotic
events on dual antiplatelet treatment has to be carried out by
methods able to explore different pathways.
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Introduction
Clopidogrel treatment along with aspirin is presently considered
the “gold standard” for attenuation of platelet activation and ag-
gregation in patients undergoing percutaneous coronary inter-
vention (PCI) (1–6).
However, despite the wide use of the antiplatelet therapy and
the significant benefits reported with combined antiplatelet
treatment in large clinical trials, adverse vascular events, includ-
ing stent thrombosis, remain a serious clinical problem that oc-
curs in a significant proportion of patients (7–8).
A growing body of evidence demonstrates that the presence
of residual platelet reactivity (RPR) on antiplatelet therapy has a
clinical relevance as it is associated with an increased risk of car-
diovascular events (9–15). In particular, clopidogrel non-respon-
siveness as assessed by light transmittance aggregometry (LTA)
induced by 10 µM adenosine 5'-diphosphate (ADP) was found to
be an independent predictor of drug-eluting stent thrombosis
(14).
LTA is considered as the standard method for the assessment
of platelet function, but point-of-care assays of platelet function
have become available, including PFA-100 (16).
Therefore, it would be necessary to develop platelet function
test/s able to better identify patients at high risk of vascular
events who could clearly benefit of a more aggressive antipla-
telet strategy and to reduce the number of false positive patients
who would be over-treated and exposed to a bleeding risk.
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To the best of our knowledge, no studies have evaluated
whether the investigation of platelet function by different agon-
ists – ADP, arachidonic acid (AA) and collagen – ameliorates the
accuracy of LTA in predicting adverse clinical events.
In the cohort of RECLOSE trial we evaluated the accuracy of
LTA by ADP, collagen and AA and of the point-of-care test
PFA-100 in predicting clinical outcomes .
Methods
Patients
We previously performed a prospective study (RECLOSE Trial)
evaluating the relationship between non-responsiveness to clopi-
dogrel by ADP-induced platelet aggregation and the occurrence
of stent thrombosis (14).
In the present study we evaluate whether the residual platelet
reactivity to AA and collagen in addition to ADP is associated
with clinical outcomes of patients receiving drug-eluting stent in
746 patients for whom complete AA- and collagen-induced pla-
telet aggregation values were available.
As previously described (14), all patients were considered
eligible for the study irrespective of clinical presentation or cor-
onary anatomy. Thus, patients with acute coronary syndromes
and ST-segment elevation acute myocardial infarction (AMI)
were included, as well as patients with left main disease, chronic
total occlusions, bifurcation lesions, or diffuse disease. The only
exclusion criteria were: 1) in-hospital death that was not due to
stent thrombosis; 2) anticipated noncompliance to dual drug
antiplatelet treatment for at least six months; and 3) premature
discontinuation of clopidogrel therapy. All patients gave in-
formed consent. The study was approved by the local ethical
committee.
PCI and antiplatelet management
All interventions were performed according to current standard
guidelines, and the type of stent implanted and the use of IIb/IIIa
inhibitors were at discretion of the operator. All patients receiv-
ed aspirin (325 mg) and a loading dose of 600 mg of clopidogrel
followed by a maintenance dose of 75 mg daily. Patients on a
maintenance dose of ticlopidine or clopidogrel at the time of ad-
mission received a loading dose of clopidogrel (600 mg).
Platelet reactivity assessment
Blood samples anticoagulated with 0.109 M sodium citrate
(ratio 9:1) for platelet reactivity assessment was obtained 12 to
18 hours (h) after clopidogrel loading. For patients receiving in
the catheterization laboratory both the loading dose of clopido-
grel and a IIb/IIIa inhibitor, blood samples were obtained after
six days while the patient was on the 75-mg maintenance dose of
clopidogrel.
Platelet-rich-plasma, obtained by centrifuging whole blood
for 10 minutes at 200 g, was stimulated with 10 µM ADP (Mas-
cia Brunelli, Milan, Italy) with 1 mM AA (Sigma-Aldrich,
Milan, Italy) and with 2 µg/ml collagen and residual drug aggre-
gation was assessed using a APACT 4 light transmittance aggre-
gometer (Helena Laboratories, Milan, Italy). The 100% line was
set using platelet-poor plasma and the 0 baseline established
with platelet-rich plasma (adjusted from 180 × 10
9
/l up to 300 ×
10
9
/l). Platelet aggregation (according to the Born’s method) was
evaluated considering the maximal percentage of platelet aggre-
gation in response to stimulus.
The coefficient of variation of ADP-LTA, AA-LTA and col-
lagen-LTA were 6.8%, 5.8% and 5.6%, respectively.
The PFA-100 system (Dade-Behring, Marburg, Germany)
simulates high-shear platelet functionwithin test cartridges. Pla-
telet function is measured as a function of the time (closure time
[CT]) that platelets take to occlude an aperture in a membrane
coated with collagen/epinephrine (CEPI) or with collagen/ADP
(CADP). Citrated whole blood sample (0.8 ml) was pipetted into
the sample reservoirs of CEPI or CADP cartridges (pre-warmed
to room temperature) and then loaded into the PFA-100 device.
Normal range (95
th
percentile of control distribution) obtained in
our laboratory was 65 to 203 seconds (s) for CT/CEPI cartridge
and 62 to 139 s for CT/CADP cartridge. The mean CV was 5.4%
for the CEPI CT in control subjects and 9.9% in patients with
CAD. The mean CVs for C/ADP CT were 4.3% in controls and
9.3% in CAD patients.
Residual platelet reactivity (RPR)
We defined patients with RPR those with platelet aggregation by
AA ≥20% and/or ADP ≥70% according to literature (17–18) and
studies from our group (14, 19). RPR by collagen was defined in
the presence of platelet aggregation induced by collagen above
90
th
percentile of patients’distribution (56%). Patients with RPR
by CEPI PFA-100 and by CADP PFA-100 were defined those
subjects with a CT/CEPI below the 90
th
percentile of controls (<
203 s) and with a CT/CADP below 68 s (19), respectively.
Endpoints
The primary endpoint of the study was definite or probable
stent thrombosis during a six-month follow-up. Definite stent
thrombosis was defined as acute coronary syndrome and
either angiographic confirmation of thrombosis or pathologi-
cal confirmation of thrombosis. Probable stent thrombosis
was defined as unexplained death or myocardial infarction in
the territory supplied by a stented vessel without angiographic
confirmation. The diagnosis of myocardial infarction was
based on either the development of new Q waves on two or
more electrocardiographic leads or an increase of creatine ki-
nase-myocardial band isoenzyme or troponin T >3 times the
upper limit of normal. Event time was categorized as acute
(within 24 h from stent implantation), subacute (from 1 day to
30 days), and late (30 days to 6 months). The secondary end
point was the composite of cardiac mortality and definite or
probable stent thrombosis.
Follow-up
All patients had scheduled clinical and electrocadiographic ex-
aminations at one, three, and six months.All other possible infor-
mation derived from hospital readmission or by the referring
physician, relatives, or municipality live registries was entered
into the database.
Statistical analysis
Discrete data are summarized as frequencies, whereas continu-
ous data as mean ± SD or median and range.
1138
Gori et al. Platelet hyperreactivity and thrombotic events
The chi-square test was used for comparison of categorical
variables. A Mann-Withney test for non-parametric data or t-test
for parametric data were used to test differences between stent
thrombosis (or composite endpoint) and no stent thrombosis (or
composite endpoint) groups.
The ability of platelet aggregation values by ADP, AA and
collagen and the PFA-100 CT/CEPI and PFA-100 CT/CADP
values (alone or in combination) to predict primary and second-
ary endpoints was examined by receiver operating character-
istics (ROC) curves. ROC curves were constructed by plotting
the sensitivity against the corresponding false-positive rate
(FPR) which equals 1-specifity. Due to the low prevalence of pri-
mary and secondary end-points, we further calculated the likeli-
hood-ratio values.
The optimal cut-off point was calculated by determining the
post-treatment RPR that provided the greatest sum of sensitivity
and specificity. Bootstrap validation was performed using R
software.
Clinical characteristics (age, sex, cardiovascular risk factors,
ejection fraction, number of vessel disease, renal failure, total
stent length, chronic total occlusion, bifurcation lesion and gly-
coprotein IIb/IIa inhibitors) were included in the logistic regres-
sion analysis as independent variables in a model in which each
RPR (RPR by ADP, RPR by ADP and AA, RPR by ADP, AA and
collagen, RPR by CEPI PFA-100 and RPR by CADP PFA-100)
was added separately. Variables that resulted not to be associated
with the outcome were removed from the final most parsimoni-
ous regression model through a backward selection algorithm.
A p-value <0.05 was considered significant. Analyses were
performed using the software package SPSS 8.0 (SPSS Inc.,
Chicago, IL, USA).
No stent
thrombosis
(n=726)
Stent
thrombosis
(n = 20)
No cardiovascular death
or stent thrombosis
(n = 721)
Cardiovascular death or
stent thrombosis
(n = 25)
Age (years) 68 ± 12 74 ± 9 * 75 ± 10 68 ± 11*
Male gender, n (%) 550 (75.8) 13 (65) 546 (75.7) 17 (68.0)
Current smokers, n (%) 165 (22.7) 5 (25) 164 (22.7) 6 (24.0)
Arterial hypertension, n (%) 450 (62.0) 15 (75.0) 447 (62.0) 18 (72.0)
Diabetes mellitus, n (%) 147 (20.2) 5 (25.0) 147 (20.4) 5 (20.0)
Hypercholesterolemia, n (%) 359 (49.4) 10 (50) 357 (49.5) 12 (48.0)
Previous myocardial infarction, n (%) 174 (24.0) 9 (45.0)§ 171 (23.7) 12 (48.0)§
Previous PCI, n (%) 165 (22.7) 5 (25.0) 163 (22.6) 7 (28.0)
Total stent length (mm) 37 ± 28 61 ± 41** 35 ± 27 52 ± 36**
Sirolimus-eluting stent, n (%) 399 (55.0) 10 (50.0) 398 (55.2) 11 (44.0)
Paclitaxel-eluting stent, n (%) 280 (38.6) 8 (40.0) 279 (38.7) 9 (36.0)
Both stent types, n (%) 47 (6.5) 2 (10.0) 47 (6.5) 2 (8.0)
Post-PCI MLD (mm) 2.88 ± 0.45 2.84 ± 0.46 2.81 ± 0.45 2.82 ± 0.52
Glycoprotein IIb/IIIa, n (%) 312 (43.0) 10 (50.0)* 311 (43.1) 11 (44.0)*
* p<0.05 vs. no stent thrombosis or no cardiovascular death or stent thrombosis. § p<0.01 vs. no stent thrombosis or no cardiovascular death or stent thrombosis. **p<0.001 vs. no stent thrombosis or no car-
diovascular death or stent thrombosis. °ST-segment elevation acute myocardial infarction.
Previous coronary artery surgery, n (%) 44 (6.1) 1 (5.0) 43 (6.0) 2 (8.0)
Stable angina, n (%) 245 (33.7) 4 (20.0) 245 (33.7) 4 (20.0)
Unstable angina, n (%) 289 (39.8) 9 (45.0) 286 (39.8) 12 (48.0) *
Acute myocardial infarction, n (%)
°
187 (25.8) 7 (35.0) 185 (25.7) 9 (36.0)
Renal failure, n (%) 80 (11.0) 3 (15 .0) 79 (11.0) 4 (16.0)
Multivessel disease, n (%) 407 (56.4) 16 (80)* 403 (55.9) 20 (80)*
LVEF (%) 47 ± 12 34 ± 13** 48 ± 11 32 ± 14**
Multivessel PCI, n (%) 407 (56.4) 16 (80) § 403 (56.2)## 20 (80)§
Thrombus-containing lesion, n (%) 155 (21.3) 3 (15.0) 153 (21.2) 5 (20.0)
Bifurcation lesion, n (%) 257 (35.4) 11 (55.6) 255 (35.4) 13 (52.0)
Chronic total occlusion, n (%) 77 (10.1) 6 (30.0)§ 76 (10.5) 7 (28.0)§
Table 1: Baseline clinical and procedural characteristics according to clinical outcomes.
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Results
Demographic and clinical characteristics according
to clinical outcomes
Demographic, clinical and procedural characteristics of the pa-
tients investigated according to clinical outcomes are presented
in Table 1.
Platelet aggregation and RPR by ADP, AA, collagen and
PFA-100 and clinical outcomes
ADP-induced platelet aggregation was significantly related with
collagen- and AA-induced platelet aggregation (rho=0.55,
p<0.001 and rho= 0.54, p<0.0001, respectively). CEPI PFA-100
values significantly correlated withADP-,AA-, and collagen-in-
duced platelet aggregation (rho=-0.26, p<0.001; rho= –0.36,
p<0.0001 and rho= –0.34, p<0.0001, respectively). Similarly in
No stent
thrombosis (n=726)
Stent thrombosis
(n=20)
No cardiovascular death or
stent thrombosis (n=721)
Cardiovascular death or
stent thrombosis (n=25)
10 µM ADP-LTA (%) n=746 45 (1–98) 56 (11–82)* 45 (1–98) 54 (11–82)*
1 mM AA-LTA(%) n=746 10 (1–92) 11.5 (2–83) 10 (1–92) 11 (2–93)
2 µg/ml collagen-LTA (%) n=176 22 (1–84) 42 (1–79)** 22 (1–84) 34 (1–79)**
CT/CEPI PFA-100 (sec)n=746 300 (75–300) 269 (85–300)** 300 (75–300) 300 (85–300)**
CT/CADP PFA-100 (sec) n=398# 106 (51–300) 79.5 (61–86)** 106 (51–300) 82.5 (61–110)**
# these data derived from 398 patients: 390 patients without stent thrombosis and 8 with stent thrombosis; 388 patients without stent thrombosis or cardiovascular death and 10 with stent thrombosis or car-
diovascular death. * p<0.05; ** p<0.01 vs no stent thrombosis or vs no composite end point (stent thrombosis and cardiovascular death).
Table 2: Platelet aggregation induced by 10 µM ADP, 1 mM AA, 2 µg/ml collagen and closure time (CT) of collagen/epinephrine
cartridges PFA-100 system.
N= 8 8.9 % **
RPR by ADP (n=90)
No RPR by ADP (n=656)
N= 6 6.7 % *
N= 14 2.1 %
N=7 5.3 % *
N= 13 2.1 %
N= 9 11.5 % **
N= 11 1.6 %
N= 9 6.8 % **
N= 11 1.8 %
N= 5 11.1 % **
N= 6 18.8 % **
N= 14 2.0 %
N= 5 20.8 % **
N= 15 2.1 %
RPR by AA (n= 131)
No RPR by AA (n=615)
RPR by Coll. (n=78)
No RPR by Coll. (n=668)
RPR by PFA-100 (n=133)
No RPR by PFA-100 (n=613)
RPR by ADP+AA (n=45)
No RPR by ADP+AA (n=701)
RPR by ADP+Coll (n=32)
No RPR by ADP+Coll (n=714)
RPR by ADP+AA+Coll (n=24)
No RPR by ADP+AA+Coll (n=722)
STENT THROMBOSIS
N=20
STENT THROMBOSIS +
CARDIAC DEATH
N=25
0 5 10 15 20 0 5 10 15 20
N= 15 2.1 %
N= 17 2.6 %
N= 17 2.8 %
N= 11 14.1% **
N= 14 2.1 %
N= 10 7.5 %
N= 15 2.4 %
N= 6 13.3 % **
N= 18 2.5 %
N= 5 20.8% **
N= 20 2.8 %
N= 19 2.7 %
N=8 6.1 %
N= 7 21.9%**
* p<0.05; ** p<0.001 vs No RPR
Figure 1: Clinical outcomes according to RPR by ADP, RPR by AA, RPR by collagen, RPR by PFA-100, RPR by AA and AA, RPR by
ADP and collagen, RPR by ADP, AA and collagen.
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398 patients in whom CADP PFA-100 was available, a signifi-
cant correlation between CADP PFA-100 values and ADP-,
AA-, and collagen- induced platelet aggregation was found
(rho=-0.28, p<0.001; rho= –0.18, p<0.0001 and rho= –0.25,
p<0.0001, respectively). Platelet aggregation by ADP, collagen
and CT/CEPI and CT/CADP values by PFA-100 system were
significantly different in patients who developed stent thrombo-
sis or secondary endpoints with respect to patients in whom no
adverse cardiovascular event was recorded (Table 2).
RPR by ADP, AA, collagen and PFA-100 system was found
in 90/746 (12.1 %), 131/746 (17.6%), 78/746 (10.5 %) and
133/746 (17.8%) patients, respectively. In 398 patients we also
evaluated CT/CADP values by PFA-100: 22/398 (5.5%) patients
had RPR by CADP PFA-100.
In Figure 1 the clinical outcomes during six-month follow-up
according to RPR by ADP, RPR by AA, RPR by collagen, RPR
by CEPI PFA-100 system and combined RPR are shown.
The presence of RPR by two stimuli, ADP and AA or ADP
and collagen, as well as by three stimuli (ADP, AA and collagen)
was significantly associated with a higher percentage of stent
thrombosis and secondary endpoints (stent thrombosis and car-
diovascular mortality) than in patients with RPR after stimu-
lation by ADP, AA, collagen and CEPI PFA-100 system (Fig. 1).
No significant association was found between RPR by CADP
PFA-100 and stent thrombosis and secondary endpoints (data
not shown).
The analysis of the aggregometry tests in relation to the pri-
mary and secondary endpoints (Table 3) demonstrated that the
sensitivity and specificity and positive predictive value of RPR
by collagen were higher than RPR byADP, byAA or by PFA-100
system, whereas negative predictive values were similar.
According to the primary and secondary endpoints, the spe-
cificity values for RPR identified by two (ADP and AA; ADP
and collagen) and three stimuli were significantly higher with re-
spect to RPR by ADP, or RPR by AA or RPR by collagen. Con-
versely, the sensitivity values were lower, but not statistically sig-
nificant, when RPR was defined after three stimuli or by two sti-
muli (ADP and AA) than only by ADP, by AA or by collagen
(Table 3). The positive predictive value significantly increased
for RPR identified by three stimuli with respect to the other
groups of RPR, where negative predictive values were similar
among different groups of RPR (Table 3).
Due to the low prevalence of primary and secondary end-
points, we further calculated the likelihood ratio (LR) values of
RPR by ADP, AA, collagen and PFA-100. As shown in Table 3,
according to primary and secondary endpoints, the detection of
RPR by three stimuli or of RPR by two stimuli (ADP and col-
lagen) is associated with a higher value of positive likelihood
ratio (Table 3).
As shown in Table 4, RPR identified by collagen, RPR by
ADP and collagen and RPR by three stimuli remained signifi-
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Table 3: Specificity, sensitivity, positive predictive value,
negative predictive value, positive likelihood (LR+), negative
likelihood (LR-) and accuracy of RPR by ADP, RPR by AA, RPR
by collagen and RPR by PFA 100 in identifying patients at risk
of stent thrombosis and composite endpoint.
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cantly associated with both primary and secondary endpoints
after adjustment for age, sex, cardiovascular risk factors, ejec-
tion fraction, number of vessel disease, renal failure, length of
stent > 20 mm, chronic total occlusion and bifurcation lesion
(Table 4).
Evaluation of different platelet aggregation cut-off valu-
es for identifying patients at high risk of adverse events
The analysis of ROC curves of the different platelet aggregation
tests showed that areas under the curves of ADP-, AA- and col-
lagen-induced platelet aggregation were 0.65 ± 0.06, 0.56 ± 0.08
and 0.50 ± 0.07, respectively.
The optimal cut-off values for platelet aggregation tests for
identifying patients at high risk of adverse events derived from
ROC curve analysis (Fig. 2) were 46% for ADP, 69% for AA,
55% for collagen, 238 s for CT/CEPI PFA-100 and 105 s for CT/
CADP PFA-100.
Sensitivity, specificity, negative, positive predictive LR+,
LR- and accuracy values, according to these cut-off values, are
shown in Table 5.
The combination of RPR by ADP (> 46%), RPR by AA
(>69%) and RPR by collagen (>55%) consistently increased the
LR+ value with respect to the “previous” cut-off values (70%,
20% and 56%).
Sensitivity, specificity and negative predictive, LR- and ac-
curacy values were similar, whereas positive predictive value in-
creased from 21 % to 26%.
Bootstrap analyses
By bootstrap analysis using 10,000 replicates, the optimal cut-
off values of ADP-, AA-, collagen-induced platelet aggregation
and PFA-100 system were 50 (95% CI 34–71), 49 (95% CI
9–79), 56 (95% CI 55–60) and 106 (95% 58–194) for primary
endpoint, and 50 (95% CI 34–72), 36 (95% CI 9–79), 55 (95% CI
Odds ratio (95% CI)
P-value
Odds ratio (95% CI)
P-value
Stent thrombosis Composite endpoint
Univariate analysis
RPR by ADP 3.28 (1.23–8.75) 0.018 3.67 (1.53–8.76) 0.003
RPR by AA 2.61 (1.02–6.69 0.045 2.29 (0.97–5.42) 0.060
RPR by collagen 7.79 (3.12–19.46) 0.0001 7.67 (3.35–17.57-) 0.0001
RPR by CEPI PFA-100 3.97 (1.61–9.79) 0.003 3.24 (1.42–7.38) 0.003
RPR by ADP and AA 5.72 (1.98–16.52) 0.001 5.52 (2.09–14.61) 0.001
RPR by ADP and collagen 12.01 (4.26–33.87) 0.0001 11.29 (4.31–25.59) 0.0001
RPR by ADP, collagen and AA 12.40 (4.09–37.64) 0.001 9.24 (3.13–27.22) 0.001
RPR by ADP and collagen 7.50 (2.40–23.43) 0.001 6.45 (2.24–18.58) 0.001
RPR by ADP, collagen and AA 6.91 (2.08–23.0) 0.002 6.42 (2.23–14.32) 0.011
Age (years) 1.05 (1.01–1.10) 0.05 1.06 (1.01–1.11) 0.014
Total stent lenght, mm 1.01 (1.00–1.02) 0.018 1.02 (1.00–1.03) 0.003
LVEF per 1% increase 0.94 (0.91–0.97) 0.0001 0.92 (0.89–0.95) 0.0001
Adjusted for traditional cardiovascular risk factors, bifurcation lesion, chronic total occlusion, multivessel disease, previous myocardial infarction, left ventricular ejection fraction and glycoprotein IIb/IIIa in-
hibitors.Variables with a p value <0.20 that were entered in the multivariate model.
Chronic total occlusion 3.16 (1.34–9.67) 0.011 3.30 (1.34–8.16) 0.010
Multivessel disease 3.10 (1.02–9.35) 0.045 3.12 (1.16–8.40) 0.025
Previous myocardial infarction 2.60 (1.06–6.37) 0.037 2.97 (1.33–6.63) 0.008
Bifurcation lesion 2.23 (0.91–5.45) 0.079 1.98 (0.89–4.40) 0.094
Age (years) 1.06 (1.01–1.11) 0.013 1.07 (1.02–1.12) 0.003
Total stent lenght, mm 1.02 (1.00–1.03) 0.0001 1.02 (1.01–1.03) 0.0001
LVEF per 1% increase 0.93 (0.90–0.96) 0.0001 0.92 (0.89–0.94) 0.0001
Multivariate analysis
RPR by ADP 2.41 (0.99–6.85) 0.090 2.86 (1.13–7.03) 0.022
RPR by AA 1.93 (0.72–5.16) 0.100 1.63 (0.65–4.09) 0.303
RPR by collagen 5.45 (2.05–14.53) 0.001 4.99 (2.05–12.17) 0.0001
RPR by PFA-100 3.25 (1.26–8.39) 0.025 2.60 (1.08–6.21) 0.031
RPR by ADP and AA 4.23 (1.36–13.10) 0.012 3.96 (1.38–11.32) 0.010
Table 4: Predictors of stent thrombosis and composite endpoint (cardiac death and stent thrombosis).
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55–55) and 108 (95% CI 58–194) for secondary endpoint. Ac-
cording to primary endpoint the area under the curve (AUC) of
ADP-, AA-and collagen-induced platelet aggregation were 0.68
(95% confidence interval [CI] 0.58–0.88), 0.58 (95% CI
0.43–0.73) and 0.61 (95% CI 0.48–0.77), whereas sensitivity
and specificity were 59% (95% CI 40–80) and 60% (95% CI
37–43) for ADP-, 25% (95% CI 10–40) and 93 (95% CI 92–94)
for AA-, 50% (95% CI 30–65) and 85% (95% CI 83–87) for col-
lagen-induced platelet aggregation. Similar results were ob-
tained for secondary endpoints (data not shown).
Discussion
To the best of our knowledge, this is the first prospective study
which has searched for the best platelet function evaluation
among three platelet-rich plasma aggregation tests and one
point-of-care test in relation to clinical events and which docu-
ments that the evaluation of platelet reactivity carried out by sti-
muli exploring different pathways represents an accurate tool for
identifying patients at risk of thrombotic events in spite of dual
antiplatelet treatment.
Our results show that the positive likelihood ratio (9.55) of
aggregometry test induced by three stimuli (ADP, AA and col-
lagen) is higher than that of ADP or ADP and AA induced aggre-
gation test, even though the sensitivity is 25%. This association
was stronger than that observed in patients with two stimuli and
in patients with RPR by only ADP.
Present findings are not inconsistent with those we pre-
viously obtained in the same patients showing that a high platelet
reactivity to ADP is a predictor of stent thrombosis (14), as in the
previous study the group of patients with RPR to ADP brings in
patients with RPR to AA and collagen.
Present results underpin the concept that no single test en-
compasses the complexity of platelet biology and function, but
that a “combination” of different stimuli has to be used to achieve
a fair detection of patients at high risk to develop adverse events.
In this study we evaluated the platelet function by using three
agonists – AA, collagen and ADP. AA-induced platelet aggre-
gation is mainly influenced by the inhibition of the thromboxane
synthesis and ADP-induced platelet aggregation is mainly sensi-
tive to the inhibition of ADP receptors, both P2Y
1
and P2Y
12
.
However, evidence exists of the role of the P2Y
12
receptor, target
of clopidogrel, as a functional regulator of TxA2 generation con-
sequent to protein-activated receptor stimulation (20) and/or,
conversely, the fact that ADP- and collagen-induced platelet ag-
gregation are affected to some extent by aspirin (21). Collagen
acts on GPVI and directly activates the receptor function of
GpIIb/IIIa to induce a maximal platelet aggregation response
(22). Signalling by these receptors causes the secretion of ADP,
which also participates in glycoprotein IIb/IIIa activation.
Figure 2: Receiver-operating characteristics (ROC) curves for different platelet function tests according to stent thrombosis.
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The relevance of platelet hyperreactivity identified by col-
lagen stimulation “per se” is underlined by the observation that
the specificity and LR+ values are higher for RPR identified by
collagen, RPR by collagen and ADP and/or AA with respect to
RPR by only ADP or AA stimuli.
In our study, the definition of high platelet reactivity as pla-
telet aggregation by ADP-LTA ≥70%, AA-LTA ≥20% and col-
lagen-LTA ≥56%, according to the literature and ourselves (14,
17–19) had low sensitivity but high specificity. By using differ-
ent cut-off values derived from the analysis of ROC curves for
RPR by ADP, AA and collagen a sensitivity higher than the valu-
es referred in the literature and in our own studies was obtained,
without remarkable changes in positive predictive and LR+ valu-
es of the single aggregometry test. Anyway, the highest LR+
value (12.96) was obtained when RPR was detected by three sti-
muli (ADP, AA and collagen).
As concerns the sensitivity, players other than haemostatic
factors participate in determining clinical outcomes. In fact sev-
eral factors including procedural characteristics (length of stent,
chronic total occlusion, bifurcation lesion), ejection fraction and
risk factors (diabetes and age) are relevant for the occurrence of
stent thrombosis in drug-eluting stents (14–15). In our study, pa-
tients with stent thrombosis, but without high platelet reactivity,
were characterized by low left ventricular ejection fraction, older
age, bifurcation lesion, and chronic total occlusion, which may
account for a significant proportion of adverse events indepen-
dently of platelet function.
In the present study we also evaluated the platelet function by
using a point-of-care test – PFA-100 system – in relation to clini-
cal outcome during the follow-up, and we found that PFA-100
test had a lower specificity with respect to the other platelet ag-
gregation tests. This assay is a global function test, which ex-
plores the capability of platelets to occlude an aperture in a mem-
brane coated with collagen/epinephrine in the presence of other
blood components, such as erythrocytes and leukocytes, that are
also involved in platelet function non-responsiveness (23–24). In
clinical trials, RPR by PFA-100 was associated with clinical
events in patients undergoing PCI (16, 25, 26). Among patients
who experienced stent thrombosis 3/20 (15%) patients had only
RPR by PFA-100, thus suggesting that this point-of-care test
gives a different picture of the hyperreactive blood which causes
thrombosis.
Recently, by using another point-of-care test designed to
measure platelet P2Y
12
receptor blockade a sensitivity of 78%
and a specificity of 68% for detecting clinical events was found
(15).
The clinical relevance of availability of accurate tests for pla-
telet function is related to the concern of the risk of bleeding
complications in relation to the administration of higher anti-
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Table 5: Specificity, sensitivity, positive predictive value,
negative predictive value, positive likelihood (LR+), negative
likelihood (LR-) and accuracy of RPR by ADP, RPR by AA, RPR
by collagen and RPR by CEPI-PFA 100 and CADP-PFA-100 in
identifying patients at risk of stent thrombosis and composite
endpoints.
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from our findings indicated that the recognition of patients at
high risk to develop stent thrombosis by using the definition of
RPR by three stimuli gave a NNT of about 5, whereas the defini-
tion of RPR by ADP, AA and collagen and by PFA-100 gave a
NNT of 22, 31, 10 and 20 respectively.
Limitations
In this study we did not explore thrombin-induced platelet acti-
vation pathway. Platelet surface expression of activated glyco-
protein IIb/IIIa and P-selectin after TRAP stimuli assessed by
flow cytometry could provide further insight into the mech-
anisms involved in the different response to antiplatelet drugs.
Second, we did not investigate platelet function by using other
whole blood-assays (28) such as the flow cytometric vasodilator-
stimulated phosphoprotein (VASP) phosphorylation assay and
VerifyNow P2Y12, which has been evaluated in detecting a re-
duced response to clopidogrel and for a platelet function-driven
antiplatelet therapy (29). Third, our study cannot provide data
about whether platelet hyperreactivity is responsible of acute
cardiovascular death (from 0 to 6 days after clopidogrel loading)
in patients who had GPIIbIIIa treatment. Finally, we do not pro-
vide information about the duration of the aspirin and/or clopi-
dogrel resistance.
Future perspectives
New point-of-care tests aimed to identify global platelet function
should use also collagen, a stimulus not specifically drug-re-
lated, but which is able to mirror a platelet hyperactive state
which renders the blood aggressive, and the patient vulnerable.
Adequately powered studies aimed to evaluate the safety of more
aggressive antiplatelet therapy should use an algorithm which in-
cludes multiple platelet aggregation tests.
In conclusion, this prospective study documents that the
evaluation of RPR is associated with thrombotic complications
and that the recognition of platelet reactivity requires the explo-
ration of different platelet multi-receptor pathways.
aggregating drug dosage or to the availability of more potent
antiaggregating drug.
De facto in TRITON TIMI 38, it was found that the lower rate
of thrombotic events was charged with higher rate of haem-
orrhagic complications in prasugrel than in patients with clopi-
dogrel (27). These findings make urgent the need of a more pre-
cise identification of patients likely to profit from additional
antiplatelet treatments, thus avoiding more aggressive treatment
of those patients who are not prone to experience stent thrombo-
sis. Interestingly, the number-needed-to-treat (NNT) calculation
What is known about this topic?
− Higher rate of clinical events in poor clopidogrel and/or
aspirin responders was documented by using different
methods to measure platelet function, but no conclusive
data about the appropriate methodology to explore pla-
telet reactivity are available.
− In particular, no studies have evaluated whether the inves-
tigation of platelet function by different agonists – ADP,
arachidonic acid and collagen − ameliorates the accuracy
of light transmittance aggregometry in predicting adverse
clinical events.
What does this paper add?
− This is the first prospective study which has searched for
the best platelet function evaluation among three platelet-
rich plasma aggregation tests and one point-of-care test in
relation to clinical events.
− It documents that the evaluation of platelet reactivity car-
ried out by stimuli exploring different pathways repre-
sents an accurate tool for identifying patients at risk of
thrombotic events on dual antiplatelet treatment.
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